Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.
Published: 22nd March 2019
Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.
Use of neoadjuvant therapy in this study of 451 procedures increased the R0 resection rate (98.4 versus 92.1 per cent, P=0.002), and improved median overall survival from 66.5 to 100.1 months: hazard ratio 0.71, 95 per cent confidence interval 0.53 to 0.96, P=0.025.Pubmed Link
You may also be interested in
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.
Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.
Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.
Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.
Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.
Authors: Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al. et al.
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.
Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466–472.
Authors: Zhang X-L, Shi H-J, Cui S-Z, Tang Y-Q, Ba M-C.
Effect of early oral feeding after gastric cancer surgery: a result of randomised clinical trial. Surgery 2011; 149: 561–568.
Authors: Hur H, Kim SG, Shim JH, Song KY, Kim W, Park CH et al. et al.
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III Trial. J Clin Oncol 2011; 29: 1715–1721.
Authors: Ychou M, Boige V, Pignon J-P, Conroy T, Bouche O, Lebreton G et al. et al.
Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg 2011; 253: 1-5.
Authors: Teoh AYB, Yan C, Philip W, Wong TCL, Liu SYW, Hung W et al. et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–697.
Authors: Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al.
Randomized phase II study of clinical effects of esophagectomy with gastric tube reconstruction. Surgery 2010; 148: 31-38.
Authors: Yamamoto K, Takiguchi S, Miyata H, Adachi S, Hiura Y, Yamasaki M et al. et al.